Titanium Dioxide Regulation

Exactly one genuine prohibition exists anywhere in the world, and it is narrow. Titanium dioxide as the food additive E171 may not be used in food manufactured or placed on the EU market since 7 August 2022, under Commission Regulation (EU) 2022/63. That is the entire inventory of bans — one substance, one use, one jurisdiction.

Set against that single withdrawal, the following uses all remain lawful as of August 2026: cosmetics and mineral sunscreens in the EU under Regulation (EC) 1223/2009; human and veterinary medicinal products in the EU; food in the United States; cosmetics in the United States; polymers intended for food contact in the United States; over-the-counter sunscreen in the United States; and industrial applications in every major jurisdiction — paints, coatings, plastics, paper, printing inks, rubber, construction materials, glass and ceramics. By volume, these industrial uses account for the overwhelming majority of all titanium dioxide consumed, and none of them is touched by the food-additive question.

The misconception follows directly from the imbalance. Reporting that says Europe banned titanium dioxide compresses a narrowly drawn food-additive withdrawal into a general prohibition, and that compression is the origin of most of the confusion among readers who ask whether titanium dioxide is banned. The practical test is simple: the same physical pigment, from the same production line, is lawful in the EU today on the shelf as a paint tin, inside a coated tablet, and in a mineral sunscreen — while being unlawful in a sweet.

The reasoning and transition periods behind the E171 decision are covered in the EU section below and in full at titanium dioxide in food.

Much of the apparent contradiction in the titanium dioxide legal status disappears once you separate three bodies of law that ask entirely different questions. Food additive authorisation law is permissive by default only in the negative sense: a substance may be used because a regulator has positively concluded it is safe for that purpose, and when that conclusion can no longer be supported, the authorisation is withdrawn — withdrawal reflects an inability to establish safety, not a finding of harm. Chemical hazard classification law does something quite different: it assigns hazard statements that travel on labels and safety data sheets so that professional users know what they are handling. It communicates; it does not authorise, restrict or prohibit any use. Occupational exposure law is different again, managing dust and aerosol exposure in workplaces through limit values, ventilation, closed systems and personal protective equipment, and it operates on its own terms regardless of what a food regulator or a classification decision says.

A parallel distinction runs through product categories. The same pigment is a colour additive under food law, an excipient or colorant in medicinal products, a listed cosmetic colorant, and a UV filter — each with a separate listing, separate maximum concentrations and separate conditions of use, sometimes differing by application form within a single category.

For formulators the operative rule is short and unforgiving: authorisation in one category never implies authorisation in another, and a decision reached under one regime is not evidence about any other. The specific instruments behind each of these regimes are cited jurisdiction by jurisdiction below.

Reading any summary of titanium dioxide regulation accurately requires distinguishing three legal states that are routinely conflated. An instrument may be in force: 21 CFR 73.575 is current law, and food manufacturers in the United States rely on it today. A proceeding may be pending: the colour additive petition docketed as CAP 3C0325 has been filed and accepted, but nothing about it changes the legal position until FDA acts on it. And a measure may be annulled: the former harmonised carcinogen entry for certain TiO2 powders under EU classification law was struck down by the courts and is no longer law, which means it cannot be cited, applied or written in the present tense. A filed petition is not a restriction; an annulled measure is not a weakened one.

Three things on this page move faster than the rest and should be re-checked before you rely on them. The FDA petition remains undecided. US state food-additive legislation changed rapidly through 2025 and continues to differ from state to state, so there is no national state-level rule to assume. And administrative follow-through after the EU classification annulment — corrected safety data sheets, labels and supplier documentation moving through supply chains — lags the legal position, so documents in circulation may still carry withdrawn wording.

Treat this page as a map to the primary sources, not a substitute for them. Before any labelling or reformulation decision, confirm the current text of the relevant CFR section, EU regulation or state statute directly. The position described here reflects the law as of August 2026.

The food listing at 21 CFR 73.575 permits titanium dioxide as a colour additive in food, with the quantity not to exceed 1 percent by weight of the food. That figure is a hard compositional ceiling written into the regulation itself, not a guidance value or a recommendation — a food exceeding it is not a food using a permitted additive at an unusual level, it is a food containing an unlisted colour additive. In practice the cap constrains the applications where opacity and whiteness matter most: confectionery panning and coatings, bakery decoration, icings, white sauces and similar products. The structural contrast with the EU is worth stating precisely. Under 21 CFR 73.575 titanium dioxide use is a question of how much; in the EU, where the additive has been delisted entirely, no concentration is lawful at all. One regime sets a limit, the other removed the entry.

Cosmetics are covered separately by 21 CFR 73.2575, which permits titanium dioxide as a colour additive in cosmetics generally, including products intended for use in the area of the eye, subject to good manufacturing practice rather than a numerical maximum. Eye-area clearance is a meaningful distinction, because many listed colour additives are expressly excluded from that use.

Food-contact materials fall under 21 CFR 178.3297, which lists titanium dioxide among the colorants permitted in polymers contacting food — pigmented packaging films, closures, containers, and components of processing equipment. Application-level formulation detail for food use is set out at titanium dioxide in food.

Sun protection is the one US pathway that sits outside colour additive law entirely. When titanium dioxide performs a UV-filtering function rather than a colouring one, it is regulated as an active drug ingredient, listed in FDA OTC Monograph M020 at section M020.10(n) at concentrations up to 25 percent. That ceiling is identical to the one zinc oxide receives at M020.10(p), which is useful context for formulators comparing mineral filter systems: neither of the two permitted inorganic filters is advantaged over the other on maximum use level, so the choice between them turns on optics, dispersion, texture and SPF efficiency rather than on any regulatory headroom.

Monograph status has a specific operational meaning. A sunscreen formulated within the conditions of the monograph — permitted actives, permitted concentrations, prescribed labelling, and the required testing for SPF, broad spectrum and, where claimed, water resistance — may be marketed without individual pre-market approval. The manufacturer does not file for clearance of the product; it takes responsibility for conformity with the monograph.

The transatlantic point resolves a persistent confusion. In the EU, the same ingredient serves the same function as a cosmetic UV filter under Annex VI entry 27 of Regulation (EC) 1223/2009. Mineral sunscreens are therefore lawful on both sides of the Atlantic, but they occupy different legal categories: a drug in the United States, a cosmetic in the EU. Anyone searching for titanium dioxide sunscreen FDA guidance is reading drug law, not cosmetic law. That categorisation difference — not any disagreement about safety — is what explains why approval routes, evidentiary requirements and timelines diverge. Formulation and product detail is covered at titanium dioxide sunscreen.

One federal proceeding is currently open on the food listing, and its status is frequently overstated in both directions. On 14 April 2023 the Environmental Defense Fund, the Center for Environmental Health, the Center for Food Safety, the Center for Science in the Public Interest and the Environmental Working Group jointly submitted a colour additive petition asking FDA to repeal 21 CFR 73.575, the listing that permits titanium dioxide in food. FDA assigned it the docket number CAP 3C0325 and published a filing notice in the Federal Register on 3 May 2023.

It is worth being exact about what that notice does. A filing notice confirms that a petition contains the information required for FDA to begin substantive review and that the agency has accepted it into the review process. It is a procedural acknowledgement. It does not signal that FDA endorses the petitioners' analysis, that the agency has reached any preliminary view, or that repeal is more or less likely. Publication opens the docket to public comment; it changes nothing in the Code of Federal Regulations.

As of August 2026, FDA has not issued a decision on the FDA titanium dioxide petition. 21 CFR 73.575 therefore remains in force, and use in food within the 1 percent ceiling remains lawful in the United States.

The scope is also narrower than commonly assumed. The petition addresses the food listing only. The cosmetic listing at 21 CFR 73.2575, the food-contact clearance at 21 CFR 178.3297 and the sunscreen monograph are not the subject of this petition. Teams tracking the file should monitor the docket directly rather than rely on secondary reporting.

The chronology is short and worth stating exactly. The instrument was adopted on 14 January 2022 and entered into force on 7 February 2022, followed by a six-month transitional window. From 7 August 2022, food containing E171 could no longer be manufactured in, or placed on, the EU market. The transition was designed to absorb goods already moving through the supply chain: product lawfully produced before the cut-off could continue to be sold to the end of its date of minimum durability or use-by date, so existing stock was drawn down commercially rather than withdrawn overnight. That window closed years ago; as of August 2026 no residual transitional relief remains anywhere in the chain.

What removal from the Union list means in enforcement terms deserves precision. Because the entry was deleted, a food containing the additive is non-compliant regardless of concentration — there is no threshold to fall below and no de minimis defence. This is structurally unlike a numerical cap, where compliance is a measurement question; here it is a listing question, and any detectable intentional use makes the product an unauthorised-additive case.

The categories affected in practice were confectionery, chewing gum, bakery decoration, sauces, soups, food supplements and coatings. The trade consequence follows directly under Commission Regulation (EU) 2022/63: product lawfully manufactured with TiO2 in the United States or elsewhere cannot be placed on the EU market, a recurring obstacle for US exporters and for co-manufactured private-label lines running a single global specification. Reformulation alternatives are covered at reformulation alternatives.

The exemption for medicinal products was deliberate, not an oversight. When E171 was removed from the Union list of food additives, titanium dioxide remained permitted as a colorant in both human and veterinary medicines, and that position has since been tested and confirmed rather than quietly carried over. The European Medicines Agency conducted a review of possible replacements, reported in April 2024, and the Commission reaffirmed the carve-out on 6 August 2025. The stated grounds were practical: no feasible alternative currently exists across the range of affected formulations, and forcing substitution would put supply at risk for roughly 91,000 human and 1,600 veterinary medicinal products.

The technical difficulty is specific to solid dosage forms. In tablet coatings and capsule shells, TiO2 delivers full opacity at very low loading, shields light-sensitive active substances from photodegradation, provides the uniform white surface that printing and identification coding require, and does so without destabilising the coating film itself. No single substitute reproduces all four properties at once, and changing a coating means revalidating stability, dissolution and, in many cases, the marketing authorisation.

Readers who see the split as a contradiction are comparing two legal regimes that ask different questions. EU food additive law and EU medicinal product law apply different tests: the latter weighs availability of the product and its therapeutic benefit against the identified concern, a calculation that has no equivalent in food law, where the additive serves no health function. The same substance can therefore be withdrawn under one framework and retained under the other without inconsistency. The position on titanium dioxide in medicines in the EU is current and in force as of August 2026.

Two separate listings under Regulation (EC) 1223/2009 govern the ingredient in personal care products, and they sit side by side: non-nano titanium dioxide is authorised as a colorant under Annex IV entry 143 and as a UV filter under Annex VI entry 27. Pigmented make-up, foundations, pressed powders and mineral sunscreens therefore remain lawful across the Union, and this part of the titanium dioxide cosmetics EU regulation was never affected by the food-additive withdrawal.

The conditions attached to that authorisation are where the analytical interest lies. In its opinion SCCS/1617/20 of 6 October 2020, the Scientific Committee on Consumer Safety considered concentrations of up to 25 percent safe in face make-up and in loose powder products, but only 1.4 percent in face-make-up sprays and 1.1 percent in loose-powder sprays. The limiting factor is inhalation of aerosolised particles, not dermal contact. That is why the same pigment is generously permitted in a cream or a pressed powder and tightly capped in a pump spray: the restriction is route-specific, not substance-wide, and reading it as a judgement on the pigment itself misses the mechanism entirely.

For formulators the consequences are concrete. Aerosol and pump-spray formats cannot simply inherit the pigment loading of their non-spray counterparts; opacity, coverage and SPF contribution must be rebuilt around a far smaller inorganic fraction, or the format reconsidered. Two checks belong in every specification review: confirm whether the grade supplied is nano or non-nano, since the applicable conditions differ, and ensure the ingredient list carries the required "nano" designation where relevant. Sunscreen-specific formulation guidance is set out at titanium dioxide sunscreen.

Published on 6 May 2021 as EFSA Journal 2021;19(5):6585, the opinion reaches its conclusion in two linked steps. EFSA stated that it could no longer establish a safe level of daily intake for E171, and it gave a single reason: a concern for genotoxicity could not be ruled out. Genotoxicity, in this context, means the potential of a substance to damage genetic material — DNA and chromosomes — whether directly or through indirect mechanisms. Because that possibility remained open, no acceptable daily intake could be derived.

Why that unresolved question was legally decisive follows from the structure of EU food additive law, which requires that safety be positively demonstrated before and while an additive stays on the Union list. The burden does not run the other way: no authority must show that an additive causes harm. Where safety cannot be affirmatively established, the authorisation cannot be maintained. An open uncertainty, not a demonstrated injury, is therefore what produced the withdrawal.

The nanoparticle fraction present in food-grade material is central to that reasoning. E171 is not a uniform powder; a proportion of its particles falls below 100 nm, and EFSA considered that these smaller particles may be absorbed and accumulate in the body. The available studies did not allow the genotoxic potential of that fraction to be characterised or dismissed, and it was this gap — uncertainty about a defined subpopulation of particles — that drove the outcome.

Read carefully, the EFSA titanium dioxide opinion 2021 records a question left open, not a hazard identified. It does not state that titanium dioxide causes cancer, and the E171 withdrawal is accordingly not a finding of harm.

Sitting on the other side of that conclusion is the reassessment carried out by the Joint FAO/WHO Expert Committee on Food Additives, which examined INS 171 at its 97th meeting and released its conclusions on 24 November 2023. The Committee reaffirmed the acceptable daily intake "not specified" originally established in 1969. Two elements carried the decision: the very low oral absorption of INS 171 from the gastrointestinal tract, and the absence of an identifiable hazard arising from dietary use. Those findings were weighed against a deliberately conservative high-end intake figure — a P95 dietary exposure estimate of 10 mg per kilogram of body weight per day — selected so that the conclusion would hold even for heavy consumers rather than for average ones.

The phrase itself is routinely misread, so the JECFA titanium dioxide ADI deserves a plain-language gloss. "Not specified" is the least restrictive outcome available within the system: it indicates that, on the data available, no numerical intake limit is considered necessary to protect the consumer. It is not a placeholder for a substance that went unevaluated, and it is not a gap in the record.

The Committee also made a methodological observation that bears directly on the divergence. Many toxicological studies in the published literature used test materials, including nanoparticles, whose size distribution and physico-chemical properties are not comparable to real-world food-grade titanium dioxide. That point matters well beyond Geneva: Codex-aligned jurisdictions outside the EU and the United States frequently follow JECFA conclusions when setting national additive rules, so this assessment underpins continued authorisation of INS 171 across much of Asia, Latin America, Africa and the Middle East.

Three drivers account for the gap, and none of them is a disagreement about what the experiments showed. The first is the nanoparticle fraction. Both bodies acknowledged that food-grade material contains particles below 100 nm; they drew opposite operational conclusions from that fact. For EFSA, unresolved uncertainty about how that fraction behaves was itself sufficient reason to say safety could not be established. For JECFA, low oral absorption meant the fraction had limited practical consequence for dietary exposure, and much of the nanoparticle literature was judged to have limited relevance to INS 171 as actually used in food.

The second is a question that precedes toxicology altogether: which studies belong in the dataset. JECFA gave reduced weight to work conducted on test materials whose size distribution and physico-chemical properties do not match commercial food-grade pigment; EFSA retained a wider body of evidence. This is a methodological judgement about admissibility, and it can reverse a conclusion without a single new experiment being run.

The third is legal rather than scientific. The precautionary principle is an explicit test in EU food law, and it pushes unresolved uncertainty toward withdrawal of an authorisation. Frameworks operating without that default generally require a demonstrable hazard before an already authorised additive is restricted — which is much of the answer to why is titanium dioxide banned in Europe but not the US.

Taken together, the divergence is best understood as a difference in evidentiary and legal method, not a factual contradiction between two records. Neither position is endorsed here. Readers who want the primary toxicological literature behind both assessments will find it at is titanium dioxide safe.